Home

 

1055 Westlakes Drive

Suite 200

Berwyn, PA 19312

© 2018 Complexa. All rights reserved.

  • LinkedIn - Grey Circle

Management

Complexa has assembled a strong management team with proven in-depth experience in the pharmaceuticals and biotech industry and a track record of success in developing and commercializing medicines to advance novel therapies and transform patient lives.

Chief Executive Officer and President

Chief Medical Officer

Chief Business Officer

Please reload

 
 
 

Chief Executive Officer and President

 

Francisco D. Salva serves as Chief Executive Officer and President. He has more than 20 years of experience in corporate development, operations, healthcare venture capital and investment banking. Prior to joining Complexa, Mr. Salva served as a Founder and Vice President of Operations for Acerta Pharma B.V., where he focused on key growth initiatives culminating in a $4 billion investment by AstraZeneca for a controlling ownership interest. While at Acerta Pharma, Mr. Salva was responsible for the company’s financial and operational activities. His responsibilities included deal analysis and negotiations, investor relationships, partnership compliance and financings. Prior to Acerta, he was Senior Director of Corporate Development at Pharmacyclics. Earlier in his career, Mr. Salva spent almost a decade as a life sciences venture capitalist at CIBC Capital Partners, INVESCO Funds Group and Patricof & Co. Ventures. He began his career at Wasserstein Perella & Co.Mr. Salva holds dual Bachelor of Arts degrees in Business Economics and Philosophy from Brown University and a Master of Science degree in Economics (Economics and Philosophy specialty) from the London School of Economics and Political Science.

Chief Medical Officer

 

Theodore (Theo) Danoff, MD, PhD, serves as Chief Medical Officer. He brings more than 20 years of experience in the pharmaceutical industry across all phases of clinical research and drug development with extensive expertise in a range of therapeutic areas, including cardiovascular, endocrinology, urology and neuroscience. Prior to joining Complexa, Theo served as Chief Medical Officer and Senior Vice President of Clinical and Medical Affairs at Clarus Therapeutics. During his tenure with Clarus Therapeutics, Dr. Danoff led the company’s clinical development efforts from Phase 1 to Phase 3 clinical trials, from strategy planning to study execution, NDA submissions, Advisory Committee presentations and FDA approval. Previously, he held senior level positions at Endo Pharmaceuticals where he supervised the overall clinical development of new products within the urology, endocrinology, pain and neuroscience therapeutic areas. While at Endo, he directed the launch of FORTESTA and oversaw the partnered development of BEMA-buprenorphine. He also led the clinical presentation at the Advisory Committee meeting for AVEED that resulted in its NDA approval. Theo began his career in pharmaceuticals at GlaxoSmithKline (GSK), serving in multiple roles of increasing responsibility, he led translational medicine studies to support new and established therapeutic areas. He has been on the faculty at the University of Pennsylvania where his NIH funded research laboratory focused on mechanisms of renal inflammation and fibrosis, and he served as an attending physician at both the Hospital of the University of Pennsylvania and the Veterans Administration Hospital (Philadelphia, PA). Theo received his MD and PhD (Immunology) degrees from the University of Chicago, where he was in the Medical Science Training Program. He completed his nephrology fellowship and residency at the University of Pennsylvania. He has received numerous research awards and has published in a number of peer-reviewed journals. He is board certified in both internal medicine and nephrology. Theo obtained his BS (highest honors) and MS in Chemistry from Emory University.

Chief Business Officer

 

Elisabeth Leiderman, MD, MBA, serves as Chief Business Officer. She brings more than 15 years of experience in the biotech, pharmaceutical and healthcare investment banking industries to Complexa with extensive expertise in multiple therapeutic areas, including oncology, cell therapy, gene therapy, rare diseases, neurology and inflammatory diseases. She has deep knowledge across a broad range of value-creating transactions such as merger and acquisition (M&A), IP/licensing, equity and debt issuances, as well as corporate/strategic planning activities. Prior to joining Complexa, she served as Senior Vice President, Head of Corporate Development for Fortress Biotech where her responsibilities included overseeing corporate and business development for 10 Fortress subsidiaries, managing and leading out-licensing transactions and efforts, and partnering with each subsidiary CEO to build the company and set overall strategy and direction. She also advised on and executed capital raises at the subsidiary levels. Previously, she served as Executive Director, Healthcare Investment Banking for Nomura Securities where she was responsible for originating and executing equity, debt, and M&A (company and product) transactions. She also held various positions with increasing levels of responsibility within the healthcare investment banking industry at Nomura Securities, Credit Suisse, UBS Investment Bank and Morgan Stanley. She began her career in Medical Affairs at AstraZeneca where she analyzed competitor drugs and emerging industry trends related to the central nervous system. Dr. Leiderman received her BA degree from University of Pennsylvania and holds an MBA from The Wharton School at University of Pennsylvania. She obtained her MD degree from the Sackler School of Medicine at Tel-Aviv University.

Please reload